The demonstration of a potent pro-tumour effect of IL-1β in PDAC allowed us to hypothesise that interference with IL-1 receptor signalling in cancer cells by suppressing COX-2 could be a promising method to sensitise PDAC cells to gemcitabine. This evidence concerns the gene IL1B and neoplasm.